<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292834</url>
  </required_header>
  <id_info>
    <org_study_id>MRCTA，ECFAH of FMU2019217</org_study_id>
    <nct_id>NCT04292834</nct_id>
  </id_info>
  <brief_title>A Registered Cohort Study of Immune-Mediated Neuropathies</brief_title>
  <official_title>A Registered Cohort Study of Immune-Mediated Neuropathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ning Wang, MD., PhD.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Fujian Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide further insights into the natural course of the disease about
      Immune-Mediated Neuropathies including clinical features，progression, related antibody
      spectrum and drug treatment effect.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 29, 2020</start_date>
  <completion_date type="Anticipated">January 19, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 19, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The correlation between clinical phenotypes and Serum antibodies</measure>
    <time_frame>from date of enrollment until the date of death from any cause,assessed up to 20 years</time_frame>
    <description>Different clinical subtypes of GBS and CIDP have different course and prognosis.It may be related to different serum antibodies.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Chronic Inflammatory Demyelinating Polyneuropathy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with GBS,CIDP,MMN who are diagnosied in the First Affiliated Hospital of Fujian
        Medical Universtiy by two neurolgists
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - 1. Outpatient or inpatient 2. Meet the diagnostic criteria of various inflammatory
        peripheral neuropathy. 3. Voluntary participation and informed consent signed by the
        applicant or his/her family.

        4. Age 18 or above

        Exclusion Criteria:

          1. Severe complications

          2. Poor prognosis (&lt;1 year survival)

          3. Severe mental disorder and inability to cooperate with the examination.

          4. Age less than 18
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lin Yi, PhD</last_name>
    <phone>86-0591-87982772</phone>
    <email>linyi7811@163.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology,First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wang Ning, PhD</last_name>
      <phone>86-0591-87982772</phone>
      <email>ningwang@fjmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Wang MD Ning, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 28, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>March 8, 2020</last_update_submitted>
  <last_update_submitted_qc>March 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Ning Wang, MD., PhD.</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

